Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis
Abstract
Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.
Related
- Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
- Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
- Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis
- Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE).
- Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort
BibTeX
@article{anno2026severe,
title = {{Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis}},
author = {Takatoshi Anno and Kazutoshi Murakami and Shuhei Nakanishi and Jun Wada and Kohei Kaku and Hideaki Kaneto and Shinji Kamei},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.6599-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6599-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis
AU - Takatoshi Anno
AU - Kazutoshi Murakami
AU - Shuhei Nakanishi
AU - Jun Wada
AU - Kohei Kaku
AU - Hideaki Kaneto
AU - Shinji Kamei
PY - 2026
DA - 2026/09/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6599-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/17/65_6599-25/_article
AB - Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.
SN - 1349-7235
SN - 0918-2918
ER -